Modification of dendritic cells (DCs) is a promising avenue for gene therapy purposes, given the versatility and the multiplicity of functions of these cells. In this study, we show that preincubation of monocyte-derived DCs with low amounts of non-infectious virion-like particles derived from the simian immunodeficiency virus (SIV MAC VLPs) increases up to 10-fold the efficiency of transduction by HIV-1 lentiviral vectors at low multiplicity of infections yielding up to 90% of transduced cells, in the absence of alterations of DCs behavior. This effect is restricted to DCs and specified by the viral accessory protein Vpx. Thus, preincubation with empty VLPs of SIV MAC can be used in transduction protocols to increase the efficacy of HIV-1-mediated modification of DCs. Gene Therapy (2006) 13, 991-994.
Dendritic cells (DCs) are pivotal players in immune system regulation 1 and thus important targets for numerous gene therapy applications. Viral-mediated gene transfer has been achieved in human monocytederived DCs with adeno and adeno-associated viruses, 2, 3 or with retroviral vectors based on lentiviruses (LVs) such as the human and simian immunodeficiency viruses and the equine anemia virus (HIV, SIV and EIAV, respectively [4] [5] [6] ). Although lentiviral transduction of DCs is clearly possible, high levels of transduced cells (from 50 to 90%) can be attained only with high viral inputs with up to 100 infectious particles per cell used in certain studies. 5, 6 Given that high viral doses have been associated with alterations of DCs phenotype and functions, 5 it would certainly be better to optimize the efficiency of cell transduction to attain high rates with a low viral input.
This goal is complicated by the experimental evidence that infection of DCs can be considered largely inefficient. For an input of 1 infectious particle per cell (referred to as a multiplicity of infection, MOI, of 1), only a few percent of DCs can be transduced, far from the theoretical transduction rate of approximately 63% that in agreement with the Poisson distribution is instead attained in cell lines such as HeLa or 293T. The same discrepancy holds true for other primary cells in which transduction rates vary, but rarely reach their theoretical value. The fact that these results can be obtained with LVs pseudotyped with envelopes with ample cellular tropism such as the vesicular stomatitis virus G protein (VSVg) that uses constitutive components of the plasma membrane as cellular receptor, argues that viral entry does not determine such differences. Rather, it suggests that the discrepancy between theoretical and experimental transduction rates evident in certain primary cells depends on the deficiency in one or more steps required for the completion of efficient infection by retroviruses.
To determine if viral proteins could help restore infection to its expected levels (by supporting a limiting positive activity or even by counteracting an antiviral cellular defense mechanism), we decided to use noninfectious virion-like particles (VLPs) as carriers for proteins normally packaged and present during infection and to determine their effect on the transduction efficiency of infectious LVs bearing a green fluorescent protein (GFP)-reporter expression cassette. To this end, infectious and non-infectious VSVg-pseudotyped LVs derived from HIV-1 and SIV MAC were similarly produced by transfection of 293T cells in the presence or absence of their respective GFP-bearing transfer genome, respectively ( Figure 1 ).
Dendritic cells were preincubated with increasing amounts of non-infectious VLPs for 2 h before infection with two different MOIs of GFP-coding SIV MAC and HIV-1 LVs (Figure 2a) . As previously reported, in the absence of preincubation, HIV-1 LVs transduced DCs, whereas SIV MAC minimal vectors did not unless Vpx was present. 4 Preincubation with HIV-1 VLPs did not modify these results. Instead, SIV MAC VLPs dramatically increased HIV-1 transduction rates of DCs up to 10-fold (from 0.5 to 40% and from 9 to 90% for MOIs of 0.5 and 5, respectively). The optimal effect of preincubation with non-infectious VLPs was obtained for MOI equivalents between 0.5 and 2.5. The increase in the percentage of transduced cells was also accompanied by an increase in their median fluorescence intensity, which was on average of the order of fivefold, and similar effects were observed if genes other than gfp were used as reporter (not shown). Similar data were obtained with minimal or complete HIV-1 LVs (i.e. in the absence or presence of viral accessory genes, not shown), whereas only Vpxdeficient SIV MAC LVs were susceptible to the positive effect of preincubation (from virtually 0 to 10% for MOI 5; Figure 2a ). Given that preincubation did not modify the infectivity of complete SIV MAC LVs (not shown), we focused on HIV-1.
To identify the SIV MAC VLPs component responsible for this effect, we proceeded to the particles' deconstruction ( Figure 2b ). The positive effect of preincubation with SIV MAC VLPs was lost in Env-deficient VLPs, demonstrating that viral entry was required for this effect. Similarly, VLPs composed of the sole Gag polyprotein did not modify HIV-1 infectivity but did so if Vpx was present. The somewhat lower effect of Gag vs complete VLPs correlated with the lower levels of Vpx present in Figure 1 Schematic representation of the vectors used here. The HIV-1-and the SIV MAC251 -based lentiviruses (LVs) 4, 9 consist in minimal and complete packaging vectors lacking or coding viral accessory proteins and their respective transfer vectors. SIV MAC Gag was expressed from a Rev-independent gag mutant, 10 the vesicular stomatitis virus G protein (VSVg) envelope from pMD.G, 9 whereas SIV MAC251 Vpx was expressed from pTG651. 4 Vesicular stomatitis virus G protein-pseudotyped LVs were produced by calcium phosphate DNA transfection of 293T cells with a Gag-Pol, transfer genome, Env mg ratio of 8:8:4. Forty-eight hours post-transfection, the supernatant containing the viral particles was filtered and purified by ultracentrifugation through a double-step sucrose cushion. Briefly, the supernatant was layered on top of two cushions of sucrose (45 and 25% w/v) and centrifuged at 28 000 r.p.m. for 2 h. The interphase between the 45 and 25% sucrose layers was then harvested, diluted three times and centrifuged again through a 25% sucrose cushion. The viral pellet was resuspended overnight in media and normalized for infectious titers (on HeLa cells) or protein content. 11 Transductions were carried out on 10 5 cells for 2 h at 371C and cells examined 72 h later by flow cytometry. Non-infectious virion-like particles were added 2 h prior transduction. Figure 2 Human peripheral blood lymphocytes (PBLs) and monocytes were obtained from healthy donors by double Ficoll/percoll separation and negative selection as previously described. 11 The monocyte population purity was 92-95%. Before transduction, macrophages and dendritic cells (DCs) were differentiated from monocytes upon culture for 4-6 days in granulocyte-macrophage colony-stimulating factor (GM-CSF) or GM-CSF plus interleukin (IL)-4, respectively (at 100 ng/ml) 11 in complete Dulbecco's modified Eagles's medium plus 5% fetal calf serum (FCS). Peripheral blood lymphocytes were treated for 24 h with 25 ng/ml of IL-7 before infection and cultured in complete RPMI 1640 plus 10% FCS. Vpx is thought to play a key role during the infection of non-dividing cells, possibly by providing a nuclear import function to viral nucleoprotein complexes. 7, 8 To determine if Vpx may yield similar levels of improvement in the transduction rates of other non-dividing cells, macrophages and IL7-PBLs, undergoing G 0 /G1 b transition but marginal cell proliferation under the conditions used here, were examined. SIV MAC VLPs did not affect HIV-1 infectivity on IL7-PBLs and only mildly did so on macrophages (two-to threefold; Figure 2c) . Similarly, preincubation with SIV MAC VLPs did not affect HIV-1 infectivity on HeLa cells nor on PHA/IL2-stimulated PBLs (not shown), strongly arguing for the specificity of this effect in DCs.
Dendritic cells can be grossly altered following LVs transduction, although this has been described for high viral inputs (seemingly at MOIs of 500). 5 We have already demonstrated that infection with SIV MAC LVs does not lead to appreciable changes in DCs physiology 4 and thus it may be assumed that preincubation with noninfectious VLPs should behave similarly. Nonetheless, to determine if this was the case, DCs were transduced with HIV-1 LVs following preincubation with SIV MAC VLPs at the maximal viral doses used for both (MOI 5; in Figure  2a ) and examined 48 h later for cell surface marker analysis. No specific changes due to viral transduction could be detected on DCs (Figure 3a) . The DCs maturation marker CD83 remained mostly negative following viral transduction and DCs largely immature (the increase of CD83, MHC class I and II molecules following stimulation with the maturation stimulus LPS is shown in black). The ability of modified DCs to mediate a strong response in allogenic mixed lymphocyte reaction was assessed next, by comparing unmodified DCs with DCs that had been transduced with HIV-1 LVs, alone or in combination with SIV MAC VLPs ( Figure  3b ). No differences were observed among these conditions, suggesting that at these low viral inputs, LVs transduction does not grossly alter DCs behavior, as previously reported. 4 Taken together, these results indicate that the efficacy of DCs transduction by HIV-1 LVs can be boosted up to 10-fold upon preincubation with non-infectious Vpxcontaining SIV MAC VLPs. SIV MAC VLPs also rescue the infectivity of minimal SIV MAC LVs (otherwise noninfectious in DCs), yet the low yields of transduced cells makes this rescue less interesting for gene therapy purposes and at most equal to the infectivity of complete (Vpx+) SIV MAC vectors. The lack of the preincubation effect on complete, Vpx-bearing SIV MAC LVs indicates that the amount of packaged Vpx is already optimal in such LVs during the infection of DCs. On the other hand, the apparent plateau in HIV transduction's rates observed in Figure 2a for increasing inputs of SIV MAC VLPs suggests that the target of Vpx can be saturated. The hypothesis can be put forward that Vpx exerts a direct action on cellular components, rather than on viral components themselves. Indeed, although an interaction with viral domains conserved among HIV and SIV cannot be a priori excluded, this hypothesis would explain both the specificity for DCs and the effect on HIV-1, a virus that does not code Vpx. Vpx may boost a pre-existing but suboptimal positive activity (as nuclear import, for example) or it may counteract an antiviral activity present specifically in DCs. At present, we ignore the exact mechanism of action of Vpx, and a detailed characterization of the effect of Vpx on the transduction of DCs is currently ongoing. Preliminary analysis of H-methyl-thymidine was added during the last 24 h of the assay before plate counting and analysis.
SIV MAC VLPs in HIV-1-mediated transduction of DCs C Goujon et al reverse transcription products in DCs indicated an increased accumulation of HIV-1 proviral DNA following SIV MAC VLPs preincubation. Synthesis of proviral DNA during viral infection is however the product of a complex equation that incorporates the rates of degradation of viral nucleoprotein complexes, of reverse transcription per se and possibly even of nuclear import. Vpx may thus exert its positive action by modulating any of these steps. The latter possibility is particularly interesting in view of the proposed function of Vpx in nuclear import, but further studies will be required to determine if this is the case. In conclusion, preincubation with noninfectious SIV MAC VLPs can be used to attain high levels of DCs transduction with low viral inputs and in the absence of gross alterations of their functions. The mostly unique action of SIV MAC VLPs on DCs rather than on other blood cell types may in principle be used in addition to cell type-specific envelopes and promoters to increase the directed targeting of DCs in vivo.
